Thromboembolic events in patients who received adjuvant chemotherapy for gastric cancer: a single-center retrospective study

Background Thromboembolic events (TEEs) are significant adverse events that can cause serious morbidities and mortality in cancer patients receiving chemotherapy. Patients with gastric cancer (GC) treated with palliative chemotherapy have been reported to experience a TEE incidence of 5–27%. However...

Full description

Saved in:
Bibliographic Details
Published in:Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2023-11, Vol.26 (6), p.1012-1019
Main Authors: Kim, Tae-Hwan, Choi, Jin-Hyuk, Jeon, Sang Min, Choi, Yong Won, Kwon, Minsuk, Lee, Hyun Woo, Kang, Seok Yun, Ahn, Mi Sun, Son, Sang-Yong, Hur, Hoon, Han, Sang-Uk, Sheen, Seung-Soo
Format: Article
Language:English
Subjects:
Abdominal Surgery
Aged
Aging
Cancer Research
Cerebral infarction
Chemotherapy
Chemotherapy, Adjuvant - adverse effects
Gastric cancer
Gastroenterology
Health risks
Humans
Hypertension
Medicine
Medicine & Public Health
Multivariate analysis
Oncology
Original Article
Oxaliplatin
Oxaliplatin - therapeutic use
Palliation
Retrospective Studies
Risk factors
Statistical analysis
Stomach Neoplasms - complications
Stomach Neoplasms - drug therapy
Stomach Neoplasms - surgery
Stroke
Surgical Oncology
Thromboembolism
Thromboembolism - chemically induced
Thromboembolism - epidemiology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Thromboembolic events (TEEs) are significant adverse events that can cause serious morbidities and mortality in cancer patients receiving chemotherapy. Patients with gastric cancer (GC) treated with palliative chemotherapy have been reported to experience a TEE incidence of 5–27%. However, very few reports have addressed TEEs in adjuvant chemotherapy (AC) for GC. Methods This study retrospectively analyzed 611 GC patients (stage II: 309, III: 302) who started AC with capecitabine/oxaliplatin (167 patients) or S-1 (444 patients) after undergoing curative resection between January 2013 and June 2020 at a single center. The incidence of TEEs during AC or within 1 year after AC completion was investigated, while analyzing the factors that influenced the TEEs’ occurrence. Results TEEs were confirmed in 20 patients (3.3%), and TEEs occurred in almost all patients in the S-1 group (19 patients). The most common TEE types were cerebral infarction and pulmonary thromboembolism (five patients each). Although old age (≥ 70 years, p  
ISSN:1436-3291
1436-3305
1436-3305
DOI:10.1007/s10120-023-01415-z